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Abstract: To better understand patterns of drug use trajectories over time, it is essential to have 
standard measures of change. Our goal here is to introduce measures we developed to quantify 
change in drug use behaviors. A secondary goal is to provide effective visualizations of these 
trajectories for applied use. We analyzed data from a sample of 92 older drug users (ages 45 to 
65) to identify transition patterns in drug use trajectories across the life course. Data were col-
lected for every year since birth using a mixed methods design. The community-drawn sample 
of active and former users were 40% female, 50% African American, and 60% reporting some 
college or greater. Their life histories provided retrospective longitudinal data on the diversity 
of paths taken throughout the life course and changes in drug use patterns that occurred over 
time. Bayesian analysis was used to model drug trajectories displayed by innovative computer 
graphics. The mathematical techniques and visualizations presented here provide the foundation 
for future models using Bayesian analysis. In this paper we introduce the concepts of transition 
counts, transition rates and relapse/remission rates, and we describe how these measures can help 
us better understand drug use trajectories. Depicted through these visual tools, measurements of 
discontinuous patterns provide a succinct view of individual drug use trajectories. The measures 
we use on drug use data will be further developed to incorporate contextual influences on the 
drug trajectory and build predictive models that inform rehabilitation efforts for drug users. 
Although the measures developed here were conceived to better examine drug use trajectories, 
the applications of these measures can be used with other longitudinal datasets.
Keywords: drug use, trajectory patterns, mixed methods, older adults
Introduction
In this paper we introduce and discuss several measures designed to evaluate the dis-
continuous patterns of drug use trajectories over the life course of older drug users. 
A trajectory is defined as “a pathway or line of development over the life span”.1(p227) 
A better conceptualization of the discontinuities of drug use patterns across the life 
course is considered essential to understanding drug use trajectories and consequences 
over time.2 For example, analysts may want to detect patterns and trends in the use 
trajectory or compare the drug use trajectories across different drugs. Clinicians might 
like to identify patterns in an individual drug user’s trajectory in order to develop a 
hypothesis regarding the influences on these patterns. Here we describe the develop-
ment of the measures that gauge the discontinuous aspects of drug use trajectories. 
Often a classification stems from an underlying characteristic that can be measured 
and subsequently used to study the phenomena. It is this characteristic that we will 
attempt to capture in a measure of discontinuity.
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Much existing research aimed at analyzing drug use 
trajectories pinpoint groups of trajectories and the possible 
causal characteristics of these.3–7 Most of these differentiate 
trajectories on the basis of their growth characteristics, that 
is, the evolution of drug use frequency over time, usually 
assessed on the basis of types of drug use level growth 
patterns.8–10 We will introduce measures to assess trajectory 
heterogeneity on the basis of the discontinuity the trajec-
tories exhibit. In contrast with growth models, here we are 
interested in significant changes of drug use in itself, not 
particularly if the change is part of a decreasing, persistent, or 
increasing trend, or belonging to a particular growth  pattern. 
We use the term discontinuity defined as a descriptive change 
in manifest behavior over the life course.2
We propose that the measures we introduce here can be 
effectively used to gauge trajectory discontinuity and that 
identifying discontinuous patterns has important implica-
tions for future research and applications. This proposition 
is supported by earlier work on continuity11 as well as more 
recent literature on substance use trajectories finding that “the 
dialectics of continuity and discontinuity still represent the 
core of development” across the life course.2(p430) A significant 
change in drug use may sometimes reflect important turning 
points in a life course; therefore the discontinuity of drug 
use trajectories may be an informative indicator in itself.12 
For example, incarceration might influence the cessation 
of certain illegal drugs, and re-entering society from prison 
might be related to using again. A more subtle transition in 
drug use might occur when a user begins a relationship with 
someone who does not use drugs, and is motivated to cease 
using. There are a myriad of influential factors on drug use 
trajectories, and having a measure of trajectory discontinu-
ity that locates transition in use helps to identify contextual 
influence by exact periods of time. As suggested by others, 
challenges in existing trajectory analyses include distinguish-
ing temporary from long-term transitions and deciding on 
the optimal time interval to capture sequences over time.2 
Although the measures developed here were conceived 
with drug use in mind, the applications of these techniques 
are not restricted to drug use alone. These measures can be 
used with other longitudinal datasets with binary variables 
representing a trajectory. How they are used depends on the 
data characteristics. Here we describe the measures using 
the characteristics of drug use trajectories.
Our goal was to evaluate the discontinuous characteristics 
of trajectories and to develop measures that can be used to 
acquire insight and/or compare the discontinuity of drug use 
of certain users and/or typical use dynamics of certain drugs. 
We gauged drug use on a 2-point scale: active (used at least 
once in a given year) and non-active (never used in a given 
year). Transitions from non-active to active, or from active 
to non-active, are notable events in such binary trajectories. 
It is the dynamics of these transitions that we aim to capture 
in the measures developed herein.
We begin by simply counting the number of transitions 
in a trajectory, which we call a transition count, and examine 
what basic properties this number expresses in the sense of 
what this particular measure tells us about the characteristics 
of the trajectory. Next, incorporating time since first use into 
the raw transition count, we define a measure of transition 
rate. These two measures are basic and are not, as is, good 
candidates for inferential extensions. On the other hand, 
they are useful tools to describe and diagnose drug use data, 
pinpoint outliers, detect patterns, and possibly percolate 
interesting hypotheses. Hypotheses are not included in this 
paper on the development of measures, but we discuss how 
they can be generated using these measures. Transition rates 
lead up to what we call relapse and remission rates, which 
measure distinct transitions from non-active to active use and 
from active use to non-active. These latter measures not only 
provide another perspective on the data, but are also more apt 
for the development of inferential statistics and, therefore, 
of generalizations and extensions.
Methods
The measures we describe in this paper were conceived as 
we attempted to analyze data we collected from older drug 
users. The goal of that research was to identify transitions 
in drug use trajectories and risk behaviors throughout the 
lives of the older adults. Existing measures of transitions 
did not fit our purposes. Here we describe the methods used 
in this study on older adult drug users to explain where and 
how the data employed to illustrate our new measures were 
derived. A sample of 92 older drug users provided the data 
analyzed to identify transition patterns in drug trajectories 
across the life course.
Sample and data collection
The data collection included both qualitative and quantita-
tive methods and analysis using a retrospective longitudinal 
design. Data were collected between August 2009 and October 
2010. To be eligible, respondents had to be at least 45 years 
old at the time of the interview and either active or former 
users of heroin, cocaine/crack or methamphetamine. These 
drugs were chosen because they represent the three major 
drugs of use associated with the most severe consequences.3,9 
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Polydrug use was the norm among our sample, as is found 
in some contemporary studies.13,14 Active use was defined as 
having used one of these drugs in the past year. Former use 
was defined as having used at least one of these drugs in the 
past ten years, for at least six consecutive months, but not 
used any of these drugs in the past year or longer. We chose 
ten years as the period within which cessation occurred in 
order to have both those who ceased use for many years as 
well as those who ceased use more recently. One year is 
chosen as the time period of no drug use since it incorporates 
the relapse period identified in a review of relapse literature.15 
Transition in drug use from active and non-active was mea-
sured in one-year time periods, which we identified to be 
the smallest period of time with a reliable amount of recall 
accuracy over the entire life course.
The study sample was recruited from the metropolitan 
area of a large southeastern city in the USA. We employed a 
combination of ethnographic mapping, snowball and targeted 
sampling methods, including field observation, community 
consultants, fliers, and referrals.16,17 These methods have 
proven effective in recruiting respondents from hidden and 
hard-to-reach populations, such as noninstitutionalized drug 
users.18–20 Guided by theoretical sampling,21 the final sample 
is diverse in terms of age, race, and years of use. About half of 
our sample identified as active users. Ages range from 45 to 
65 years old. About half of the sample is African  American, 
four identified as “other” (American Indian or Latino), and 
the remainder white. A little over 40% of the sample is 
female. About a quarter have a high school education or 
its equivalency, with almost 60% reporting some college 
experience or more. For this paper, the sample characteristics 
are not important in the development of the transition and 
discontinuity measures other than its diversity in terms of 
drug use trajectory heterogeneity, which is why an older user 
sample with a long drug history was advantageous.
We developed an innovative combination of quantitative 
and qualitative strategies to collect life history interviews. 
The life history interview is a research tool designed to 
provide data with distinguishable transitions throughout 
the life course.22,23 The life histories of older adults provide 
rich retrospective longitudinal data on the diversity of paths 
taken throughout the life course and changes that occur over 
time.1,24–27 The data provided self-reported histories of drug 
use, risk behaviors and social contextual variables.
A well-developed body of research shows that the valid-
ity of self-reported data is increased when a number of 
proven methods are employed.28–32 For example, providing 
interviewers and respondents with a form of self-checking,33 
establishing rapport,34 and using cues, such as a historical 
event timeline, helps ensure reliable data is collected on 
substance use and abuse.35 Challenges to the reliability and 
validity of longitudinal data include two forms of biases: 
recall accuracy and social desirability.36 While self-reports 
in cross-sectional and prospective longitudinal designs have 
fewer recall challenges than those collected in retrospective 
designs, they are influenced by social desirability biases 
that limit reporting of stigmatized or illegal behaviors.23,37 
 Retrospective data is less prone to this kind of social 
desirability effect and has the advantage of being cheaper 
to gather, as opposed to prospective longitudinal designs.38 
Additionally, using a mixed methods design has been shown 
to be particularly important to avoid the problems associated 
with social desirability.37,39 Our retrospective longitudinal and 
mixed method design incorporated all of these strategies to 
provide reliable and valid data.
Potential respondents were screened to ensure compli-
ance with the eligibility criteria. Interviews were conducted 
face-to-face in a private setting which would make the 
respondent feel at ease. Two well-trained interviewers 
were present with each respondent during the interview and 
continually cross-checked the data as it was collected. The 
entire interview process lasted between three and five hours. 
Respondents were offered food and given $40 at the end 
of the interview. Reimbursement for respondents has been 
shown to be ethical and effective when collecting research on 
stigmatized behaviors such as drug use.40,41 The Institutional 
Review Board at the investigators’ university approved the 
interview protocol.
Both quantitative and qualitative data were collected 
concurrently using a computer assisted personal interview 
(CAPI) and audio-recorded in-depth interview. Interviews 
began with the in-depth narrative interview wherein the 
respondents were free to discuss their life story with 
minimal guidance by the interviewer. Interviewers wrote 
important events, social roles, and behaviors on a paper 
life history matrix that allowed them to organize and keep 
track of time-specific facts and events in the life of the 
respondents. The matrix and notes informed and guided 
the interviewers as they collected the data on the  computer 
survey. Inconsistencies and gaps in the respondent’s 
stories could be quickly and easily caught and clarified 
by interviewers, enhancing the reliability of the survey 
data. Additionally, a timeline with important historical 
events was provided to the respondents to help give them 
memory cues and historical context in which to place events 
in their lives. For example, respondents were reminded 
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that “this was the year Kennedy was shot” as data were 
 collected for 1963. Diverse timelines were developed to 
be culturally sensitive.
Variables
The survey consisted of questions about residence, family, 
work, relationships, health, education, and criminal justice 
involvement and drug use for every year. Questions used 
for this paper regard yearly use and non-use of each of the 
following drugs: tobacco (TOB); marijuana (MAR); alcohol 
(ALC); hallucinogens (HAL); cocaine (COC); crack cocaine 
(CRK); heroin (HER); amphetamine (AMP); methamphet-
amine (MET) and prescription pill misuse (PRP). Prescrip-
tion pills were reported as active use only when they were 
obtained illegally or when a prescription was being misused. 
Other drug use variables (eg, route of administration, addic-
tion severity) were collected but not used in the analysis for 
this paper.
Drug use frequency, recorded on an 8-point scale, was 
re-coded to a 2-point scale so that drug use of a given user at 
a given age (year) is expressed by one of two values:
0: Non-active (never used drug X that year)
1: Active (used drug X at least once that year)
A binary measure has several advantages: 1) it enables 
a more parsimonious description and discussion of the 
 measures we developed; 2) it attends to issues regarding 
the validity of self-reported data (ie, recall of use and  non-use 
each year over many years is plausibly more valid than recall 
of frequency of use for every year over the life course); 
3) the transitions between use and non-use are probably more 
noteworthy than any other transition between two drug use 
levels and probably reflect a major change in the user’s drug 
career; 4) analyzing such binary trajectories complements 
the existing growth models perspective since the latter 
 cannot really be applied to binary trajectories as they stand, 
 without adapting the usual definitions and interpretations 
(for example, what would a “steadily increasing” drug use 
trajectory be if use were to only be captured by a binary 
variable?); 5) the difference between growth aspects and 
discontinuity aspects of trajectories is not so clear when 
looking at multiple use levels of drug use trajectories.
Descriptive statistics for trajectory 
discontinuity
In the following we describe how and why the measures and 
visualizations we used were developed, based on analysis 
of our study data. For the sake of brevity, we first use hypo-
thetical examples to explain the foundational development 
and  progression of the measures. We follow this with 
 visualizations of actual users selected from our study sample 
that illustrate the measures and their potential applied use.
Drug use trajectory
The (binary) trajectory of a user for a specific drug is fully 
described by a sequence, T, of 0s and 1s specifying the drug 
use of a respondent for each age of the life of a user (starting 
at age 0 and ending at the age the user was at the time of the 
interview). The left-most digit corresponds to 0 years old and 
digits are grouped by groups of five to facilitate readability. 
For example, consider the following hypothetical trajectory 
for tobacco:
 T = 00000 00000 01111 11111 10000 00000 111.
This trajectory describes a user who took tobacco for 
the first time at 11 years old. The user then continuously 
(meaning “at least once a year”) used tobacco until 21 years 
old when she stopped, only to start again at 30 years of age 
and remain active until 32 years of age, at the time she was 
interviewed.
Trajectory discontinuity
The discontinuous patterns of all drug trajectories are visual-
ized in the following graphs that include both drug use and 
selected risk behavior variables, based on two individual 
users drawn from our study. The images in Figure 1 exhibit 
the trajectories of two actual users for each of the 10 drugs 
in the survey. A row represents a trajectory for a given drug 
over the life of the individual. A black shaded cell for a given 
age (x-axis) and drug (y-axis) represents active use (1) and 
a non-shaded cell non-active (0).
As shown, both respondents depict long stretches of 
active use of tobacco and both have used a diversity of 
drugs in their lives. While respondent 113 has had longer 
periods of using heroin and crack that reveal a discontinu-
ous pattern of active and non-active years, respondent 026 
has a more discontinuous pattern of using prescription pills 
and drinking alcohol. Recall that prescription pills are 
included only when they are misused or obtained illegally. 
Although 113 reports many years of self-reported problem-
atic drug use, as seen in the row labeled “problematic”, 
alcohol does not appear to be a problematic substance in 
his life. We can easily see that this respondent has had over 
20 years of continuous treatment and is non-active for all 
drugs in the past three years. Contrast this with respondent 
026 who, although he is in treatment the year he was 
interviewed, has had few continuous years of treatment 
and has not stopped his illegal use of prescription drugs. 
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Both respondents have hepatitis C and have spent time in 
prison or jail. The graphs present a parsimonious descrip-
tion for the variables of interest over an entire life course. 
Later in this paper, we return to these two respondents 
to show how measures of discontinuity can be used to 
estimate the probability that a user will remain active or 
non-active in the next year for specific drugs based on 
their trajectories.
The graphs are presented here to better visualize the mea-
sures of discontinuous trajectory patterns that we explain in 
the next section in more detail. The risk variables are shown 
here only to illustrate future applications of the model and 
are not further explored in this paper. We also do not address 
the numerous causal influences on transitions in drug use, 
since it is beyond the scope of this paper. As mentioned 
previously, many aspects of a life course will affect and be 
affected by drug use. For example, loss of employment or 
divorce may result in a relapse and conversely, acquiring 
a new job or spouse may influence cessation of use. We 
leave causal influences on drug use for a future application 
of the techniques we describe here. In this paper, our aim 
is to describe the development of measures that gauge the 
discontinuous aspects of drug use trajectories. Firstly we will 
introduce several descriptive statistics based on the number 
of transitions that appear in drug use trajectories. We will 
discuss what particular aspects of a trajectory these measures 
convey and illustrate this using the trajectory visualizations 
from our older drug user study.
HIV
HepC
Risky sex partners
Risky condom use
Prison
Treatment
Problematic
MET
AMP
HER
CRK
COC
PRP
HAL
MAR
ALC
TOB
HIV
HepC
Risky sex partners
Risky condom use
Prison
Treatment
Problematic
MET
AMP
HER
CRK
COC
PRP
HAL
MAR
ALC
TOB
5 10 15 20 25 30 35 40 45 55 6050
Age
5 10 15 20 25 30 35 40 45 5550
Age
Respondent 113: Male African American. Education: Some college
Respondent 026: Male white. Education: High school diploma/GED
Figure 1 Drug use trajectories of all drugs and selected risk variables for two respondents.
Note: Black shaded cell represents active use.
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Transition count
We start with a straightforward measure that we will refer to 
as transition count (TC). The TC of a trajectory T is defined 
to be the number of sequential transitions from 0 (non-active) 
to 1 (active) or from 1 (active) to 0 (non-active). For example, 
consider the following hypothetical trajectory for alcohol:
    T = 00000 00111 10000 1111.
The transition count of T is TC(T) = 3. Indeed, our hypo-
thetical user started (as all users do) with a sequence of 0s 
and had his first alcoholic drink at age 7. This is the first 
transition (from non-active to active). The transition count for 
our hypothetical case is incremented by one. The user drank 
at least once a year until age 10, but did not drink when he 
was 11 years old. This is the second transition (from active 
to non-active), so the transition count is incremented again. 
Nothing changed until age 15 when the user drank again, 
and the transition count is incremented once more. Since our 
hypothetical user continued drinking until age 19, the age he 
was when he was interviewed, his transition count is 3, shown 
by the three bolded numerals indicating a transition.
Transition count aspects are fundamental in the analysis 
of drug use trajectories. They provide a single descriptive 
statistic that captures several characteristics and can therefore 
be a useful statistic to diagnose the data, such as identifying 
outliers and uncovering biases. For example, the transition 
count encodes several noteworthy properties of trajectories: 
1) if the TC is 0, it means that the individual never used that 
particular drug; 2) a TC of 1 means that the individual started 
and never stopped the drug (at the level of year-by-year 
observations); 3) a TC of 2 means that the individual used 
the drug at some point, but then stopped indefinitely (that is, 
until the time of the interview); 4) an even TC means that 
the individual is NOT currently (at the time of the interview) 
using the drug; and 5) an odd TC means that the individual 
is currently using the particular drug.
Transition counts can also be used to compile descriptive 
tables to compare the dynamics of specific drugs. Table 1 
displays the range of TCs (0–12) found in our sample of 
older drug users, as well as the frequency distribution of 
respondents that fell into each TC bracket for every drug 
for all 920 trajectories (92 respondents for 10 drugs). The 
range of TCs shows the large variation among users. For 
example, some respondents reported that they never used 
marijuana (TC = 0), while one respondent reported transition-
ing 12 times before discontinuing marijuana. Table 2 shows 
the frequency distribution of trajectories as percentages for 
each TC count for every drug. Viewing the data in frequency 
tables allows us to compare the trajectories for each drug 
and identify interesting trends in our data. For example, 
Table 2 indicates that the majority of respondents (56.5%) 
never quit using tobacco once they begin while the majority 
of respondents who had used hallucinogens (42.4%) discon-
tinued use and never took this drug again.
However, the transition count has some shortcomings in 
emulating how one might commonly compare the disconti-
nuity of several trajectories. One critical inadequacy is that 
transition count alone does not take into account the amount 
of time the user has had to accrue these transitions, and this 
could be misleading. For example, consider the following 
two hypothetical trajectories in Figure 2.
If we base our judgment on the transition count, respon-
dent Y has a more discontinuous use pattern than respondent X. 
To make the matter of comparing the discontinuity of a trajec-
tory more pertinent to the dynamics of a user once he/she is 
exposed to the given drug, we suggest it is more appropriate 
to only consider dynamics during the period since the first use 
of the drug. If we extrapolate the drug use of respondent X to 
the same span of use as that of respondent Y, then respondent 
X displays much more discontinuity. To capture this we need 
a measure evaluating the tendency of a user to transition rather 
than the number of transitions itself.
Transition rate
One straightforward way of integrating the duration of the 
respondent’s career with a drug into a transition count is to 
divide the latter by the number of years since the year of first 
use. We thus define the transition rate (TR) of a trajectory 
only for trajectories with non-null transition counts (null 
meaning the participant never used this drug) as follows:
TR = (TC-1)/number of years since first use.
The transition rate gives us a sense of how often transi-
tions occur during the respondent’s career with this drug.
In our hypothetical example above, respondent X has 
a TR of (5 − 1)/9 = 0.4444 and respondent Y has a TR of 
(7 − 1)/45 = 0.1333, thereby conveying that respondent X’s 
drug use is considerably more discontinuous than respon-
dent Y’s drug use. Transition rates are comprised between 
0 (corresponding to a respondent that uses every year since 
the onset) and 1 (corresponding to a trajectory that toggles 
from active to non-active every year).
Transition rates let us see the duration of the career with the 
number of transitions for each individual. So for example, if 
someone has a TC of 4 but started 20 years ago and still uses, 
this is not such a discontinuous career as someone with a TC 
of 4 who started only 4 years ago. Unlike TCs, the TRs range 
over many unique values. To better compare these ranges, 
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Table 1 TC frequency count
Drugs
TOB ALC MAR HAL PRP COC CRK HER AMP MET
TC frequency count
0 9 6 4 37 37 11 18 32 50 54
1 52 22 12 1 6 6 17 8 1 3
2 8 24 36 39 21 34 23 17 32 17
3 15 11 13 0 4 4 9 5 0 8
4 3 10 16 12 11 22 13 16 7 7
5 3 7 2 0 6 3 6 3 0 1
6 0 3 4 3 2 8 3 7 1 2
7 2 5 1 0 3 0 1 2 0 0
8 0 1 1 0 2 3 1 2 0 0
9 0 1 1 0 0 0 1 0 0 0
10 0 1 1 0 0 1 0 0 1 0
11 0 1 0 0 0 0 0 0 0 0
12 0 0 1 0 0 0 0 0 0 0
Abbreviations: TOB, tobacco; ALC, alcohol; MAR, marijuana; hAL, hallucinogens; PRP, prescription pill misuse; COC, cocaine; CRK, crack cocaine; heR, heroin; 
AMP, amphetamine; MeT, methamphetamine; TC, transition count.
Table 2 TC frequency distribution
Drugs
TOB ALC MAR HAL PRP COC CRK HER AMP MET
TC frequency distribution (in %)
0 9.8 6.5 4.3 40.2 40.2 12.0 19.6 34.8 54.4 58.7
1 56.5 23.9 13.0 1.1 6.5 6.5 18.5 8.7 1.1 3.3
2 8.7 26.1 39.1 42.4 22.8 37.0 25.0 18.5 34.8 18.5
3 16.3 12.0 14.1 0.0 4.3 4.3 9.8 5.4 0.0 8.7
4 3.3 10.9 17.4 13.0 12.0 23.9 14.1 17.4 7.6 7.6
5 3.3 7.6 2.2 0.0 6.5 3.3 6.5 3.3 0.0 1.1
6 0.0 3.3 4.3 3.3 2.2 8.7 3.3 7.6 1.1 2.2
7 2.2 5.4 1.1 0.0 3.3 0.0 1.1 2.2 0.0 0.0
8 0.0 1.1 1.1 0.0 2.2 3.3 1.1 2.2 0.0 0.0
9 0.0 1.1 1.1 0.0 0.0 0.0 1.1 0.0 0.0 0.0
10 0.0 1.1 1.1 0.0 0.0 1.1 0.0 0.0 1.1 0.0
11 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
12 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Abbreviations: TOB, tobacco; ALC, alcohol; MAR, marijuana; hAL, hallucinogens; PRP, prescription pill misuse; COC, cocaine; CRK, crack cocaine; heR, heroin; 
AMP, amphetamine; MeT, methamphetamine; TC, transition count.
5
Respondent X, TC = 5
10 15 20 25 30 35 40 45 5550
5
Respondent Y, TC = 7
10 15 20 25 30 35 40 45 5550
Figure 2 Transition count trajectories.
Notes: Line represents age trajectory in years. Black shaded area represents active use for given years
Abbreviation: TC, transition count.
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we computed the frequencies over 11 defined categories 
(brackets), which encompass a percentile range of values. To 
compute these values we performed a number of statistical 
calculations including: 1) normalizing the TRs within a same 
drug using z-scores; 2) taking the mean of these z-scores to 
describe an average discontinuity of a respondent over all drugs; 
3) taking the z-score of this mean to see where this general 
discontinuity lies compared to other respondents.
Tables 3 and 4 show the bracketed TRs calculated from the 
z-score of the mean of the z-scores of the TRs, as described 
above. These cumulative frequency percentages help us to com-
pare the distribution of the TRs for one drug with the general 
TR distribution for all drugs. The first bracket contains those 
TRs equal to 0 (started and never stopped use of the drug), 
since a good number of trajectories fall under this category. The 
subsequent 10 brackets are defined by the deciles of the TRs for 
all respondents and all drugs. These deciles are 0.0250, 0.0286, 
0.0323, 0.0435, 0.0625, 0.0769, 0.0932, 0.1197, 0.1613.
Table 3 shows the range of TRs found in our sample, 
as well as the frequency count of respondents that fell into 
each TR bracket for every drug. Unlike the 0 in the TC, 
a TR equal to 0 means that, at the time of the interview, the 
respondent has continued to use a particular drug every year 
since initiating use and never stopped. Table 4 displays the 
frequency distribution of trajectories as percentages for each 
TR bracket for every drug. As with the TC tables (Tables 1 
and 2), these tabular representations help us compare the TRs 
for each drug to clarify trends in our sample.
We include these tables to illustrate how the measures 
and statistics depicted can be used to generate hypotheses 
regarding trends, patterns, and comparisons between the 
trajectories of different drugs. For example, Table 4 shows 
that 27% of CRK users or former users fall in the last “TR 
greater or equal to 0.1613” bracket. This is the highest percent 
in this bracket for all drugs. This value of 0.1613 is the 90th 
percentile of TRs over all drugs, meaning that 90% of all 
defined TRs are smaller than this value. The fact that 27% of 
CRK users have this transition rate level speaks again of the 
highly discontinuous behavior of CRK use, compared to the 
behavior with other drugs in our sample. Further examination 
of these tables is beyond the scope of this paper. Instead we 
move to the next step in our development of measures to 
gauge trajectory discontinuity.
The transition rate exhibits the tendency to transition 
from one drug use state to another, but it does not indicate 
whether the transitions are from active use to non-active or 
vice versa. Consider the following hypothetical trajectories 
shown in Figure 3.
Remission rate and relapse rate
Respondents V and W both have same transition rate and 
transition count, yet there is a noteworthy difference between 
them. Respondent V was active most of his life, with the 
exception of a few short remissions into non-use; whereas, 
by contrast, respondent W was non-active most of her life 
with the exception of a few short relapses into use. The 
transition count and rate aggregate remissions and relapses, 
without taking into account the respective durations of the 
periods they initiate.
The transition rate is in fact an estimate of the underlying 
probability to transition from one state to another. We will 
define the remission and relapse rates so as to be estimates 
of the underlying probability to transition from non-active 
to active and from active to non-active, respectively. This 
Table 3 TR frequency count of respondents in each percentile bracket
Sample size Drugs
TOB ALC MAR HAL PRP COC CRK HER AMP MET
83 86 88 55 55 81 74 60 42 38
TR frequency count
TR = 0 52 22 12 1 6 6 17 8 1 3
0.0000 , TR , 0.0250 4 9 9 6 2 4 0 1 6 0
0.0250 ,=TR , 0.0286 2 3 11 16 4 9 0 4 13 3
0.0286 ,= TR , 0.0323 0 9 12 8 8 2 0 2 5 2
0.0323 ,= TR , 0.0435 2 3 4 8 2 18 9 3 8 0
0.0435 ,= TR , 0.0625 13 9 11 1 3 2 3 5 0 8
0.0625 ,= TR , 0.0769 1 5 10 4 4 4 5 4 2 5
0.0769 ,= TR , 0.0932 4 6 5 8 8 11 5 10 4 3
0.0932 ,= TR , 0.1197 3 6 4 1 9 10 5 8 1 6
0.1197 ,= TR , 0.1613 2 9 5 2 4 8 10 9 1 3
0.1613 ,= TR 0 5 5 0 5 7 20 6 1 5
Abbreviations: TOB, tobacco; ALC, alcohol; MAR, marijuana; hAL, hallucinogens; PRP, prescription pill misuse; COC, cocaine; CRK, crack cocaine; heR, heroin; 
AMP, amphetamine; MeT, methamphetamine; TR, transition rate.
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type of model of a sequence of states is typically known as 
a “Markov Model” or “Markov Chain” and is defined as a 
sequence of states having the property that the next state 
depends only on the current state.
A Markov Chain specifies the probability of the next state 
of the sequence conditional on the current state. In our case 
we have two states (0 and 1), so four transition probabili-
ties need to be specified, namely Prob(0→0), Prob(0→1), 
Prob(1→0), and Prob(1→1). In Markov Chain terminology, 
not only 0→1 and 1→0, but also 0→0 and 1→1 are called 
“transitions”. That is, respondents can take 1 of 4 states in 
any given year: no transition from nonuse, transitioning from 
nonuse to use, transition from use to nonuse, and no transi-
tion from use. Let us take the trajectory of respondent V as 
an example. As in the case of the transition rate discussed 
above, we will only consider the sub-trajectory  corresponding 
to the interval between the onset of drug use (first year that 
this drug was used) and the year of the interview. In the 
case of respondent V, we consider therefore the following 
trajectory:
10111 11111 10001 11111 11111 11111 00000.
To estimate the probabilities of each possible type of 
transition, we count the number of 0 s and 1 s and the number 
of sequential pairs 00, 01, 10, and 11:
• #0: Number of 0 s = 8
• #00: Number of 00 s = 6
• #01: Number of 01 s = 2
• #1: Number of 1 s = 26
• #10: Number of 10 s = 3
• #11: Number of 11 s = 23
From this information, we can estimate the probabilities 
of every possible sequential pair:
• Prob(0→0) ∼ #00/#0 = #00/(#00 + #01) = 6/(6 + 2) = 0.75
• Prob(0→1) ∼ #01/#0 = #01/(#00 + #01) = 2/(6 + 2) = 0.25
Table 4 TR frequency percentage in each percentile bracket
Sample size Drugs
TOB ALC MAR HAL PRP COC CRK HER AMP MET
83 86 88 55 55 81 74 60 42 38
TR frequency percentage
TR = 0 62.7 25.6 13.6 1.8 10.9 7.4 23.0 13.3 2.4 7.9
0.0000 , TR , 0.0250 4.8 10.5 10.2 10.9 3.6 4.9 0.0 1.7 14.3 0.0
0.0250 ,= TR , 0.0286 2.4 3.5 12.5 29.1 7.3 11.1 0.0 6.7 31.0 7.9
0.0286 ,= TR , 0.0323 0.0 10.5 13.6 14.6 14.6 2.5 0.0 3.3 11.9 5.3
0.0323 ,= TR , 0.0435 2.4 3.5 4.5 14.6 3.6 22.2 12.2 5.0 19.1 0.0
0.0435 ,= TR , 0.0625 15.7 10.5 12.5 1.8 5.5 2.5 4.1 8.3 0.0 21.1
0.0625 ,= TR , 0.0769 1.2 5.8 11.4 7.3 7.3 4.9 6.8 6.7 4.8 13.2
0.0769 ,= TR , 0.0932 4.8 7.0 5.7 14.6 14.6 13.6 6.8 16.7 9.5 7.9
0.0932 ,= TR , 0.1197 3.6 7.0 4.5 1.8 16.4 12.4 6.8 13.3 2.4 15.8
0.1197 ,= TR , 0.1613 2.4 10.5 5.7 3.6 7.3 9.9 13.5 15.0 2.4 7.9
0.1613 ,= TR 0.0 5.8 5.7 0.0 9.1 8.6 27.0 10.0 2.4 13.2
Abbreviations: TOB, tobacco; ALC, alcohol; MAR, marijuana; hAL, hallucinogens; PRP, prescription pill misuse; COC, cocaine; CRK, crack cocaine; heR, heroin; 
AMP, amphetamine; MeT, methamphetamine; TR, transition rate.
5
Respondent V: TC = 6, TR = 5/34 = 0.1471
10 15 20 25 30 35 40 45 5550
5 10 15 20 25 30 35 40 45 5550
Respondent W: TC = 6, TR = 5/34 = 0.1471
Figure 3 Transition rate trajectories.
Notes: Line represents age trajectory in years. Black shaded area represents active use for given years.
Abbreviations: TC, transition count; TR, transition rate.
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• Prob(1→0) ∼ #10/#1 = #10/(#10 + #11) = 3/(3 + 23) = 0.12
• Prob(1→1) ∼ #11/#1 = #11/(#10 + #11) = 23/
(3 + 23) = 0.88
This transition probability specification is commonly 
represented as a directed graph or “digraph”.42 The directed 
graphs and transition matrices shown in Figure 4 were gen-
erated for hypothetical respondents V and W. Once again, 
1 represents active use in a given year and 0 non-active 
use of the drug in a given year. The percentages next to 
the directional arrows indicate the likelihood of remaining 
active (or non-active) in the next year or transitioning from 
active to non-active and vice-versa.
We see that respondent V tends to remain a user from year 
to year, with only a 12% chance of having a remission. Once 
a non-user again, he has a 75% chance of remaining so every 
year, but a non-negligible 25% chance of relapsing into use. In 
contrast, respondent W, when in an active use year, has a 50% 
chance of a remission the next year. Once a non-user again, she 
tends to remain so, only relapsing into use with a 7% chance.
Note that the 0→0 and 1→1 can be deduced from the 
0→1 and 1→0 probabilities, respectively. Indeed, these are 
inverse probabilities of each other. Hence the Markov chain 
transition probabilities are fully specified from the 0→1 and 
1→0 transition probabilities only. These rates are calculated 
only from the first year of use onward. This brings us to the 
following definitions:
The relapse rate is the ratio of non-using years that were 
followed by a relapse into a using year. That is, the relapse 
rate is the number of 01s divided by the number of 0s (or 
equivalently, the sum of 01s and the 00s).
The remission rate is the ratio of using years that were 
followed by a remission into a non-using year. That is, the 
relapse rate is the number of 10s divided by the number of 1s 
(or equivalently, the sum of 11s and the 10s).
Technically, relapse and remission rates can be seen as 
estimating the corresponding probabilities of an underlying 
Markov Chain model. In this model, each state is given a prob-
ability to be in that state the following year, given the state of 
the current year. Since drug use is measured here with a binary 
variable, the model is fully specified by two probabilities: the 
relapse probability (that the non-using respondent will use the 
following year) and the remission probability (that the using 
respondent will not use the following year). The probability that 
the non-using respondent will remain non-active the following 
year is one minus the relapse probability. The probability that 
the using respondent will remain active the following year 
is one minus the remission probability. To specify a Markov 
Chain completely, one should also specify a probability for the 
initial state of the sequence. Since we are considering trajec-
tories and computing our rates only from the first year of use 
onward, our initial state will always be 1 (active user).
We combine both the transition count trajectory with the 
Markov Chain model depicted in the diagraph into one graph 
to provide a more complete view of the user’s drug trajec-
tory and probability for remission and relapse. Figures 5–8 
illustrate the drug trajectories and digraphs for the two actual 
respondents we discussed previously. We use alcohol and 
heroin trajectories for the purpose of comparison.
Comparing the trajectories and digraphs of two respon-
dents’ life use of alcohol and heroin, we see the trajectories 
reveal different patterns of discontinuity for each drug. 
Recall that the trajectory represents every year of life. The 
black shaded cells indicate active use that year (at least 
once) and the non-shaded cells indicate non-active. In this 
1
Respondent V
88%
0
75%
25%12%
1
Respondent W
50%
0
93%
7%50%
Figure 4 Directed graphs.
Notes: 0 represents non-active use in a given year. 1 represents active use in a 
given year.
0 10 20 30 40 50 60
73%
Resp #026 -- Drug: ALC
Age
14% 27%
86%
Figure 5
Notes: Trajectory line represents every year of life. Black shaded cell represents 
active use in a given year.
Abbreviation: ALC, alcohol.
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hand, 026 is an active drinker in the year he was interviewed 
and, with a more discontinuous pattern of drinking and long 
periods of active use, he has an 86% probability of remaining 
active next year. These probabilities are almost completely 
reversed when looking at their heroin trajectories.
While both respondents show discontinuous patterns of 
heroin use, they are quite different. We see that 026 started 
using heroin at age 13, and he stopped and started again in a few 
years’ span before remaining non-active for almost 30 years. He 
was active for two years in his late forties and them remained 
non-active until the time of the interview. Instead, 113 started 
heroin later in life, at age 19, used for a few years, stopped 
one year and then remained active for almost twenty years. 
He stopped using heroin for another 9 years  followed by a 
period of continuous active use for a 9-year span. While both 
are non-active at the time they were interviewed, the digraphs 
show that 113 has a 15% probability of relapsing the next year 
while 026 has only a 5% probability.
Space does not permit us to present the trajectory and 
digraph for all drugs used by 026 and 113, and a fuller 
description is beyond the scope of this paper. Yet, the trajec-
tories for all drugs can be seen in the earlier graphs shown in 
Figure 1, and a brief discussion on this provides insight on 
the usefulness of these measures. Taking into consideration 
the drugs used each year shown in the graph for 026, he 
appears to have switched from using heroin to prescription 
pills. The qualitative interview (not presented here) revealed 
these are pain pills, which can act as a substitute for heroin. 
In addition, he has not stopped his drinking. By some treat-
ment standards, 026 would not be viewed as rehabilitated or 
0 10 20 30 40 50 60
Resp #113 -- Drug: ALC
Age
97%
50% 3%
50%
Figure 6
Notes: Trajectory line represents every year of life. Black shaded cell represents 
active use in a given year.
Abbreviation: ALC, alcohol.
0 10 20 30 40 50 60
95%
Resp #026 -- Drug: HER
Age
50% 5%
50%
Figure 7
Abbreviation: heR, heroin.
0 10 20 30 40 50 60
Resp #113 -- Drug: HER
Age
85%
10% 15%
90%
Figure 8
Notes: Trajectory line represents every year of life. Black shaded cell represents 
active use in a given year.
Abbreviation: heR, heroin.
graph, the grey shaded area starts the year after the age the 
respondent was interviewed: 026 was interviewed at age 
56 and 113 at age 61. The digraphs based on their trajectories 
show quite different probabilities for remission and relapse 
depending on the drug.
First we see that the respondents started alcohol at dif-
ferent ages (026 at age 13 and 113 at age 19). However, 
the trajectory of 026 shows a more discontinuous pattern, 
while 113 shows only a few years of active drinking around 
his twenties. Moreover, 113 has not had an alcoholic drink 
for almost 40 years, while 026 is drinking in the year of the 
interview. The digraphs reveal that 113 has a 97% probabil-
ity to remain non-active in regards to alcohol. On the other 
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“in recovery”. By contrast, 113 ceased all drugs and alcohol 
use for the last three years. Most treatment providers would 
consider 113 rehabilitated or at least in long term recovery. 
However, as shown above in the heroin digraph, while 113 
has a considerable probability to remain in remission, he 
also has a greater probability for relapse than does 026 for 
heroin use. This outcome is the result of taking into account 
the discontinuity measures found in their life trajectories.
Based on our measures of transition counts and transition 
rates, the relapse and remission rates we compute from a 
trajectory can be used as estimates of the underlying relapse 
and remission probabilities of a given user for a given drug. 
Our objective in this article to develop measures that gauge 
the discontinuous patterns of a drug use trajectory are sub-
sumed in these simple discontinuity statistics. Moreover our 
secondary goal to develop graphic models that describe the 
data visually is achieved through the trajectory graphs and 
digraphs presented here.
Conclusion
In this paper we responded to a number of methodological 
challenges to the identification of discontinuity in drug use 
trajectories.2 Framed in a life course perspective that includes 
both intra-individual change and inter-individual differences 
in trajectories across the life course, we distinguished tem-
porary perturbations from long-term change.1 Using person-
period data from life history interviews with older drug 
users, we suggested the “year” as an optimal time interval. 
Furthermore, to better assess a trajectory, we proposed to 
collect yearly data from birth. We identified discontinuity 
in the yearly trajectory of drug use by analyzing the transi-
tions from active to non-active (and vice-versa). Counting 
the total number of transitions, as measured by the transi-
tion count, was shown to be a useful subsuming measure 
of several fundamental types of trajectories. Incorporating 
the number of years since drug use onset, the transition 
rate gives us a more appropriate measure of discontinuity 
since it provides a sense of how often a user transitions. The 
relapse and remission rates take this further by exhibiting 
the contributions of transition from non-active to active use, 
and active to non-active, respectively. The new measures and 
statistics depicted in these tables and graphs can be used to 
identify trends and patterns, and compare the trajectories 
of different drugs or different groups of drug users. They 
provide a succinct way to model large event-history data 
sets that make it easier for researchers and practitioners to 
generate hypotheses and further their exploration on respec-
tive research questions.
In this paper, we developed measures to assess the dis-
continuity of drug use trajectories; however the measures 
can be employed with any sequence of binary variables. 
Here we applied them to drug use data in order to describe 
the development of the measures and to illustrate how they 
can be used. The developments of these measures and 
illustrative graphs have a number of potential applications for 
drug research and treatment. For example, the discontinuity 
measures presented here respond to the call for different 
approaches to address risk behaviors and the risk environment 
of drug users.43,44 By expanding on the measures shown 
here, we can develop inferential statistics to assess the risk 
of relapse and remission. Inferential statistics will also 
allow us to make better estimates of the underlying prob-
abilities involved, thereby generating better estimates of the 
underlying activity and discontinuity of any risk behavior 
trajectory for which we have valid data.
Limitations
The assertions made here about the characteristics of the 
users and the drugs are purely descriptive of the sample, being 
only intended to articulate certain aspects that our measures 
exhibited. Used alone, these measures do not illustrate the 
whole picture. However, they can be used for comparing 
similarities and differences in the drug user trajectory across 
different drugs and for individual drug users. These measures 
and graphic visualizations provide a useful tool to gauge tra-
jectory discontinuity. Hypotheses can be generated from the 
visualizations shown here, but validating such hypotheses will 
require developing inferential statistics based on these descrip-
tive statistics. Inferential statistics provide tools to extend 
beyond the data itself and assess the validity of assertions 
about a more general context. We provided some indications 
on how such inferential statistics may be developed, but the 
development and discussion of these inferential statistics and 
their application will be left to future articles.
Future research and applied use
In this methodological paper we proposed new measures 
that provide tools to analyze discontinuous trajectories and 
support hypotheses generated by the graphic illustrations 
of these measures applied to data. Measuring and concep-
tualizing discontinuous patterns in individualized drug use 
has important implications for future research on drug use 
trajectories and potentially for predicting turning points in 
risk behaviors. Aggregated transition counts and transition 
rates may be used to compare trends in drug use patterns, 
across specific drugs, and across the life course of individual 
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users. In addition, the visualization models presented here 
provide a parsimonious understanding of an individual user’s 
life history of drug use and its association with selected 
variables. These measures can be modified and extended 
to predict risk of relapse, measured with the precision to 
individual differences and specific socio-contextual associa-
tions. Drug rehabilitation practitioners have identified a gap 
in research for individualized treatment approaches.45,46 The 
relapse and remission rates provide predictive value based 
on the user’s life history and individualized trajectory, visu-
ally depicted in the digraphs. Our development of trajectory 
discontinuity measures is not finished. In future papers we 
will explore many more aspects of the trajectory, differences 
between types of drug users, active and inactive users, and 
other characteristics of the sample, as well as inferential 
statistical applications that incorporate the influence of 
social-contextual events over the life course. We envision 
eventual application of these models for drug treatment and 
rehabilitation purposes, as well as the development of health-
care intervention, prevention programs, and policy.
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